717 / 1835
•
90
Y-Ibritumomab consolidation confers a durable PFS benefit for
patients with advanced FL
• 3-year PFS advantage for patients in the ITT population
• At least a 6-year PFS advantage for patients with a
CR/CRu after induction > 5-year advantage in time to next
treatment
• No unexpected toxicities emerging
Annualized rate of secondary MDS/AML was 0.55% in the
Zevalin arm
FIT TRIAL
Conclusions after 7 years Fol low-up